KLRK1 and hepatocellular carcinoma: To this end, expression of CD62L and CD57 were examined on PBMC after overnight stimulation with LCC or HCC, or with cross-linking antibody to the NK cell activating receptor CD16, or a cocktail of antibodies to NK cell activating receptors (NKp30, NKp46, NKG2D and CD2) (Fig. 2).